A Phase II Study of Carboplatin (CBDCA). Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Carboplatin (Primary) ; Everolimus (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Biomarker; Therapeutic Use
- 16 Nov 2015 Results published in the Annals of Oncology (n = 45).
- 21 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 22 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.